Compare Mesoblast Limited (MESO) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Ryanair Holdings plc — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.81B), while Ryanair Holdings plc trades at $54.61 (market cap $27.95B). The key difference: Ryanair Holdings plc is far larger — about 15.4× Mesoblast Limited's market cap, and Ryanair Holdings plc pays a 1.6% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Ryanair Holdings plc for 72 Days on average.
| MESO | RYAAY | |
|---|---|---|
Market Cap | $1.81B | $27.95B |
Volume | 240,620 | 1,519,820 |
Sector | Health | Industrials |
52-Week High | $20.96 | $73.82 |
52-Week Low | $13.19 | $51.95 |
Typical Hold Time | 14 Days | 72 Days |
Enterprise Value | $1.89B | $25.00B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
RYAAY trades at $56.00 with a slight 0.24% daily gain, showing mixed technical signals amid bearish moving averages but neutral oscillators. Fundamentally, the airline maintains strong profitability with 12.13% net margins and attractive valuation multiples (P/E 13.95, EV/EBITDA 6.22), though recent Q3 2026 earnings are pending against high expectations. Analyst sentiment leans bullish with 65% buy ratings, but news highlights fuel cost pressures and Boeing MAX 10 certification delays as near-term concerns.
The stock presents a value opportunity given low valuations and robust cash flow, but investors face headwinds from oil price volatility and operational challenges. Upside hinges on Q3 earnings beat and cost management, while downside risks include prolonged certification delays and weaker winter traffic. Institutional ownership trends and dividend stability ($0.44 upcoming) provide support, but macro uncertainties warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
